S1351 Improvement in Fatigue With Mirikizumab Therapy and Associations With Clinical Outcomes in Patients With Moderately to Severely Active Crohn's Disease: Results From the PHASE 3 VIVID-1 Study

Peter Bossuyt,Miguel D Regueiro,Monika Fischer,Kristina Traxler,Guanglei Yu,Marijana Protic,Konstantinos Tsilkos,Aisha Vadhariya,Tadakazu Hisamatsu,Pascal Juillerat
DOI: https://doi.org/10.14309/01.ajg.0001034772.24547.f5
2024-10-26
The American Journal of Gastroenterology
Abstract:Fatigue is a debilitating, multifactorial symptom experienced by many patients with Crohn's disease (CD). Mirikizumab (MIRI), an anti-interleukin-23p19 antibody, demonstrated significant improvement in fatigue in patients with moderately to severely active CD in the Phase 2 AMAG and Phase 3 VIVID-1 studies.
gastroenterology & hepatology
What problem does this paper attempt to address?